- Global Pharma News & Resources

Anorexia Nervosa Market Surpassed USD 90 Mn in 2021, Impelled by Increasing Frequency of Dietary Diseases | insightSLICE

The global Anorexia Nervosa market size was estimated to be US$ 90 million in 2021 and is expected to grow at a CAGR of 15% between 2023 to 2032.

Anorexia Nervosa is a disorder that results in lack of appropriate weight gain, or excess weight loss due to extremely decreased consumption.

People with anorexia generally have restricted diets and consume very low amounts of calories compared to a normal person. This condition is defined by patient-initiated and persistent weight reduction. It most typically affects teenage girls and young women, although it can also affect teenage boys and young men, as well as many youngsters entering puberty and older women during menopause.

The illness is related to unique psychopathology, in which patients have an obsessive, inflated fear of morbid obesity and excess pessimism about body shape, which results in the imposition of a low weight limit on themselves. Frequently some degree of malnutrition, and consequent endocrine and metabolic abnormalities along with body function impairments are also present in patients diagnosed with Anorexia Nervosa.

Access the sample report:

Global Anorexia Nervosa Market Key Segments:

Based on Psychological Therapy:

  • Individual therapy (insight-oriented)
    • Cognitive analytic therapy
    • Cognitive behavioral therapy (CBT)
    • Family-based therapy (FBT)
    • Specialist supportive clinical management (SSCM)
    • Others
  • Pharmacologic Therapy
  • Others (Medications and Supplementary Diet via Counselling)

Based on End User:

  • Hospitals
  • Clinics
  • Homecare
  • Others

Based on Geography

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Dietary restrictions, intense exercise, forced vomiting, and the consumption of prescription medications and diuretics to reduce appetite are all signs of such deliberate anorexia. This causes a fundamental disturbance in daily routines and severely restricts daily nourishment. Therefore, individuals will suffer from secondary problems as they have severely reduced nutrition.

Anorexia nervosa is a serious mental disease that may have a profound influence on all parts of a person’s life from physiological to social. The sooner any eating disorder is discovered and treated, the better the chances of healing or enhanced life quality.

The key players of the Global Anorexia Nervosa Market are:

Various companies and associations have been involved in providing treatment or therapy services for anorexia nervosa patients. The organizations that lead the global anorexia nervosa market are EDH, Timberlines Knolls, Eating Disorders Victoria, NEDC, National Association of Anorexia Nervosa, and others.

Driving factors for the growth of Global Anorexia Nervosa Market

Anorexia nervosa treatment must tackle both psychological and physiological issues and often requires both a mental health expert and a healthcare doctor. The primary goal of anorexia nervosa therapy is to regularize dietary habits and adopt measures that aid in weight maintenance.

The secondary goal is to alter misguided views and ideas that encourage restrictive eating behavior. As a result, ongoing therapy and nutrition education are critical components of complete healing. Psychotherapy for dietary issues is generally delivered in a group setting. The major strategy for the treatment team comprises medical professionals such as dietitians or physicians, as well as psychological wellness experts.

Constant patient treatment, frequent therapy, dietary counseling, and medication are also important components of successful therapy. Even though some antidepressants are prescribed to treat anorexic behaviors, they have not always been successful, and no medicine has been authorized by the FDA to address it.

Doctors need to monitor bone loss, blood electrolyte imbalances, and heart health whereas psychologists can assist a person in overcoming self-destructive beliefs and habits and embracing a more optimistic view.

Awareness of restricted eating behavior patterns has increased healthcare literacy in developing countries, and general anorexia nervosa therapeutic knowledge is propelling worldwide markets to stable expansion in the next few years.

Various lifestyle choices such as smoking, genetic illnesses, alcoholism, and strenuous exercise are also main determinants of the worldwide anorexia nervosa and people associated with such disorders drive the global anorexia nervosa treatment market.

Read more about the report inclusions:

Challenges of Global Anorexia Nervosa Market

Patient stigmatization and refusal to acknowledge their condition are one of the biggest problems for the growth of the anorexia nervosa market.

Furthermore, the majority of existing alternative treatments are non-pharmacological, including professional advice and guidelines, hindering the growth of the anorexia nervosa treatment industry. Furthermore, there is a dearth of instructors and professionals to speak with patients and raise public awareness.

Related reports:

Global Protein Expression Market:

Global Human Recombinant Insulin Market:

The leading market segments of Global Anorexia Nervosa Market

Antidepressants, antipsychotics, and mood stabilizers may also be advantageous in the treatment of anorexia nervosa and other co-occurring conditions like anxiety or depression. However, drugs such as olanzapine, aripiprazole, and dronabinol, which are commonly used to treat anorexia nervosa patients, lack standardized therapy, limiting their adoption by both physicians and patients. These reasons are also contentious factors hampering the growth of the anorexia nervosa market for therapy and treatments.

Quetiapine, an atypical antipsychotic, looks to be a good therapy option for AN. It has been reported to aid with both mental and physical benefits in modest dosages, with few accompanying adverse effects. Prozac is another prospective medication used as an SSRI (selective serotonin reuptake inhibitor) that prevents mood fluctuations.

This medication may aid in the treatment of depression symptoms as well as maintaining a normal weight once the expected body weight has been accomplished. If approved by regulatory bodies the drug-based treatment approach will make a significant impact on the anorexia nervosa treatment market.

New drug discovery and better psychotherapy methods are expected to increase the treatment options available for anorexia nervosa patients and in turn propel the anorexia nervosa market to new heights.

Proceed to purchase:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 08-Nov-2022